A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

Inclusion Criteria

• •All subjects:
• •Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.
• •Male and female subjects aged between 18 and 79 years (inclusive) at screening.
• •Body mass index (BMI) of 18.0 to 34.0 kg/m2 (inclusive) at screening. Body weight of at least 50 kg.
• •Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day-1. They must consistently and correctly use (from at least first dosing, during the entire study, and for at least 30 days after last study treatment intake) a highly effective method of contraception with a failure rate of \< 1% per year and must use condoms, diaphragm or cervical cap with spermicide, or be sexually abstinent. Hormonal contraceptive must be initiated at least 1 month before study treatment administration.
• •Renal function impairment subjects:
• •At screening and on Day -1, the stage of renal function impairment will be defined by Creatinine Clearance (CLcr) by the Cockcroft-Gault (C-G) equation:
• •Mild renal function impairment: CLcr 60-89 mL/min (Group A).
• •Moderate renal function impairment: CLcr 30-59 mL/min (Group B).
• •Severe renal function impairment: CLcr \<30 mL/min (Group C).
• •The stage of renal impairment will need to be confirmed at Day -1 and the CLcr values on Day -1 will need to remain within ± 25% of the screening value.
• •Healthy subjects:
• •Normal renal function confirmed by a CLcr ≥ 90 mL/min. Normal renal function will need to be confirmed at Day -1 and the CLcr value on Day -1 will need to remain within ± 25% of the screening value.